Theralase® Provides Update on Phase II Bladder Cancer Clinical Study
April 05, 2022 07:00 ET
|
Theralase Technologies Inc.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Antibody Drug Conjugates (ADCs) Market Size to Reach USD 13.17 Billion by 2028 - Powered by Approval for Biologics License Applications – Vantage Market Research
February 15, 2022 04:39 ET
|
Vantage Market Research
WASHINGTON, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research’s recent analysis of the Global Antibody Drug Conjugates (ADCS) Market finds that granted accelerated approval for biologics...
Cancer Support Community Launches New Study Focused on Bladder Cancer
February 10, 2022 16:25 ET
|
Cancer Support Community
PHILADELPHIA, PA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), the world’s largest provider of cancer support with a network of 175 locations across the United States and...
Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight
January 31, 2022 13:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight Non-Muscle Invasive Bladder Cancer Pipeline...
Worldwide Immuno Oncology Assays Industry to 2026 - Clinical Trials to Cure Different Cancers in Immunotherapy Presents Opportunities
January 05, 2022 06:38 ET
|
Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Immuno Oncology Assays Market Research Report by Indication, Product, Technology, Application, and Region - Global Forecast to 2026 - Cumulative Impact...
First Patient Dosed in Study of Targeted Alpha Therapy Candidate for Bladder Cancer
December 20, 2021 16:45 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and NANTES, France, Dec. 20, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. (‘ATONCO’) today announce that...
Theralase Expands Intellectual Property Portfolio
December 09, 2021 07:00 ET
|
Theralase Technologies Inc.
TORONTO, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research...
Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Solid Tumors at ESMO Congress 2021
September 14, 2021 08:00 ET
|
Aprea Therapeutics
BOSTON, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate...
Theralase Releases Q221 Unaudited Financial Statements and Quarterly Newsletter
August 30, 2021 18:15 ET
|
Theralase Technologies Inc.
TORONTO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), A clinical stage pharmaceutical company dedicated to the research...
Imagin Medical on Schedule for American Urology Association Demonstration
August 17, 2021 08:30 ET
|
Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Aug. 17, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the...